Background
Methods
Patients
Blood sample analysis
Statistical analysis
Results
Clinicopathological features
Parameters | Number of patients (n = 118) (%) |
---|---|
Age at operation (years old) | 51 (30–78) |
Symptoms | |
Asymptomatic / Symptomatic | 42 (35.6%) / 76 (64.4%) |
Palpability | |
Impalpabe / Palpable | 33 (28.0%) / 85 (72.0%) |
Tumor size (mm) | 17.7 (3.0–50.0) |
Biopsy device | |
Core needle biopsy / Vacuum-assisted biopsy | 67 (56.8%) / 51 (43.2%) |
Estrogen receptor | |
Negative / Positive | 22 (18.6%) / 96 (81.4%) |
Progesterone receptor | |
Negative / Positive | 37 (31.4%) / 81 (68.6%) |
HER2 | |
≤ 2 / 3 | 101 (85.6%) / 17 (14.4%) |
Ki67 | |
≤ 14% / > 14% | 98 (83.1%) / 20 (16.9%) |
Grade of DCIS | |
Low, intermediate / High | 98 (83.1%) / 20 (16.9%) |
Comedonecrosis | |
Absence / Presence | 54 (45.8%) / 64 (54.2%) |
Intraductal calcification | |
Absence / Presence | 99 (83.9%) / 19 (16.1%) |
Lymphoid infiltrate | |
Negative, mild / moderate, severe | 83 (70.3%) / 35 (29.7%) |
Postoperative pathology | |
DCIS only / Invasive ductal carcinoma | 70 (59.3%) / 48 (40.7%) |
Platelets–lymphocyte ratio | median 138.9 (range, 55.0–292.0) |
Low / High | 70 (59.3%) / 48 (40.7%) |
LDH | median 170 (range, 121–452) |
≤ ULN / >ULN | 105 (89.0%) / 13 (11.0%) |
CEA | median 1.6 (range, < 0.5–12.4) |
≤ ULN / >ULN | 111 (94.1%) / 7 (5.9%) |
CA15–3 | median 6.6 (range, < 0.5–40.8) |
≤ ULN / >ULN | 115 (97.5%) / 3 (2.5%) |
Correlations between clinicopathological features and postoperative pathology
Parameters | Postoperative pathology | p value | |
---|---|---|---|
DCIS only (n = 70) | Invasive ductal carcinoma (n = 48) | ||
Age at operation (years old) | |||
≤ 60 | 50 (71.4%) | 33 (68.8%) | |
> 60 | 20 (28.6%) | 15 (31.3%) | 0.754 |
Symptoms | |||
Asymptomatic | 30 (42.9%) | 12 (25.0%) | |
Symptomatic | 40 (57.1%) | 36 (75.0%) | 0.044 |
Palpability | |||
Impalpabe | 24 (34.3%) | 9 (18.8%) | |
Palpable | 46 (65.7%) | 39 (81.3%) | 0.065 |
Tumor size (mm) | |||
≤ 20.0 | 48 (68.6%) | 23 (47.9%) | |
> 20.0 | 22 (31.4%) | 25 (52.1%) | 0.024 |
Biopsy device | |||
Core needle biopsy | 32 (45.7%) | 35 (72.9%) | |
Vacuum-assisted biopsy | 38 (54.3%) | 13 (27.1%) | 0.003 |
Estrogen receptor | |||
Negative | 9 (12.9%) | 13 (27.1%) | |
Positive | 61 (87.1%) | 35 (72.9%) | 0.051 |
Progesterone receptor | |||
Negative | 18 (25.7%) | 19 (39.6%) | |
Positive | 52 (74.3%) | 29 (60.4%) | 0.111 |
HER2 | |||
≤ 2 | 63 (90.0%) | 38 (79.2%) | |
3 | 7 (10.0%) | 10 (20.8%) | 0.100 |
Ki67 | |||
≤ 14% | 60 (85.7%) | 38 (79.2%) | |
> 14% | 10 (14.3%) | 10 (20.8%) | 0.352 |
Grade of DCIS | |||
Low, intermediate | 63 (90.0%) | 35 (72.9%) | |
High | 7 (10.0%) | 13 (27.1%) | 0.015 |
Comedonecrosis | |||
Absence | 37 (52.9%) | 17 (35.4%) | |
Presence | 33 (47.1%) | 31 (64.6%) | 0.061 |
Intraductal calcification | |||
Absence | 62 (88.6%) | 37 (77.1%) | |
Presence | 8 (11.4%) | 11 (22.9%) | 0.098 |
Lymphoid infiltrate | |||
Negative, mild | 56 (80.0%) | 27 (56.3%) | |
Moderate, severe | 14 (20.0%) | 21 (43.8%) | 0.006 |
Platelets–lymphocyte ratio | |||
Low | 50 (71.4%) | 24 (50.0%) | |
High | 20 (28.6%) | 24 (50.0%) | 0.018 |
LDH | |||
≤ ULN | 63 (90.0%) | 42 (87.5%) | |
> ULN | 7 (10.0%) | 6 (12.5%) | 0.670 |
CEA | |||
≤ ULN | 66 (94.3%) | 45 (93.8%) | |
> ULN | 4 (5.7%) | 4 (5.7%) | 0.904 |
CA15–3 | |||
≤ ULN | 69 (98.6%) | 46 (95.8%) | |
> ULN | 1 (1.4%) | 2 (4.2%) | 0.353 |
Parameters | Platelets–lymphocyte ratio | p value | |
---|---|---|---|
Low (n = 74) | High (n = 44) | ||
Age at operation (years old) | |||
≤ 60 | 51 (68.9%) | 32 (72.7%) | |
> 60 | 23 (31.1%) | 12 (27.3%) | 0.661 |
Symptoms | |||
Asymptomatic | 29 (39.2%) | 13 (29.5%) | |
Symptomatic | 45 (60.8%) | 31 (70.5%) | 0.290 |
Palpability | |||
Impalpabe | 22 (29.7%) | 11 (25.0%) | |
Palpable | 52 (70.3%) | 33 (75.0%) | 0.580 |
Tumor size (mm) | |||
≤ 20.0 | 45 (60.8%) | 26 (59.1%) | |
> 20.0 | 29 (39.2%) | 18 (40.9%) | 0.854 |
Biopsy device | |||
Core needle biopsy | 42 (56.8%) | 25 (56.8%) | |
Vacuum-assisted biopsy | 32 (43.2%) | 19 (43.2%) | 0.995 |
Estrogen receptor | |||
Negative | 15 (20.3%) | 7 (15.9%) | |
Positive | 59 (79.7%) | 37 (84.1%) | 0.556 |
Progesterone receptor | |||
Negative | 25 (33.8%) | 12 (27.3%) | |
Positive | 49 (66.2%) | 32 (72.7%) | 0.461 |
HER2 | |||
≤ 2 | 63 (82.4%) | 40 (90.9%) | |
3 | 13 (17.6%) | 4 (9.1%) | 0.205 |
Ki67 | |||
≤ 14% | 62 (83.8%) | 36 (81.8%) | |
> 14% | 12 (16.2%) | 8 (18.2%) | 0.783 |
Grade of DCIS | |||
Low, intermediate | 60 (81.1%) | 38 (86.4%) | |
High | 14 (18.9%) | 6 (13.6%) | 0.460 |
Comedonecrosis | |||
Absence | 36 (48.6%) | 18 (40.9%) | |
Presence | 38 (51.4%) | 26 (59.1%) | 0.666 |
Intraductal calcification | |||
Absence | 63 (85.1%) | 36 (81.8%) | |
Presence | 11 (14.9%) | 8 (18.2%) | 0.635 |
Lymphoid infiltrate | |||
Negative, mild | 49 (66.2%) | 34 (77.3%) | |
Moderate, severe | 25 (33.8%) | 10 (22.7%) | 0.204 |
LDH | |||
≤ ULN | 67 (90.5%) | 38 (86.4%) | |
> ULN | 7 (9.5%) | 6 (13.6%) | 0.484 |
CEA | |||
≤ ULN | 70 (94.6%) | 41 (93.2%) | |
> ULN | 4 (5.4%) | 3 (6.8%) | 0.753 |
CA15–3 | |||
≤ ULN | 71 (95.9%) | 44 (100.0%) | |
> ULN | 3 (4.1%) | 0 (0.0%) | 0.176 |
Postoperative pathology | |||
DCIS only | 50 (67.6%) | 20 (45.5%) | |
Invasive ductal carcinoma | 24 (32.4%) | 24 (54.5%) | 0.018 |
Univarite analysis | Multivarite analysis | |||||
---|---|---|---|---|---|---|
Parameters | Odd ratio | 95% CI | p value | Odd ratio | 95% CI | p value |
Age at operation (years old) | ||||||
≤ 60 vs > 60 | 1.136 | 0.510–2.531 | 0.754 | |||
Symptoms | ||||||
Asymptomatic vs Symptomatic | 2.250 | 1.004–5.042 | 0.047 | 2.226 | 0.638–8.463 | 0.217 |
Palpability | ||||||
Impalpabe vs Palpable | 2.261 | 0.941–5.434 | 0.065 | 0.865 | 0.201–3.568 | 0.842 |
Tumor size (mm) | ||||||
≤ 20.0 vs > 20.0 | 2.372 | 1.111–5.063 | 0.024 | 2.647 | 0.908–8.261 | 0.075 |
Biopsy device | ||||||
CNB vs VAB | 0.313 | 0.142–0.690 | 0.003 | 0.201 | 0.068–0.534 | 0.001 |
Estrogen receptor | ||||||
Negative vs Positive | 0.397 | 0.154–1.023 | 0.051 | 1.008 | 0.227–4.633 | 0.991 |
Progesterone receptor | ||||||
Negative vs Positive | 0.528 | 0.240–1.163 | 0.111 | |||
HER2 | ||||||
≤ 2 vs 3 | 2.368 | 0.832–6.744 | 0.100 | 1.739 | 0.361–8.417 | 0.484 |
Ki67 | ||||||
≤ 14% vs > 14% | 1.579 | 0.601–4.149 | 0.352 | |||
Grade of DCIS | ||||||
Low, intermediate vs High | 3.343 | 1.221–9.155 | 0.015 | 2.234 | 0.526–9.961 | 0.274 |
Comedonecrosis | ||||||
Absence vs Presence | 2.045 | 0.961–4.350 | 0.061 | 0.817 | 0.303–2.133 | 0.682 |
Intraductal calcification | ||||||
Absence vs Presence | 2.304 | 0.850–6.248 | 0.098 | 2.525 | 0.748–9.019 | 0.136 |
Lymphoid infiltrate | ||||||
Negative, mild / moderate, severe | 3.111 | 1.373–7.046 | 0.006 | 2.296 | 0.752–7.215 | 0.144 |
Platelets–lymphocyte ratio | ||||||
Low vs High | 2.500 | 1.160–5.386 | 0.018 | 3.526 | 1.423–9.258 | 0.006 |
LDH | ||||||
≤ ULN vs > ULN | 1.286 | 0.404–4.094 | 0.670 | |||
CEA | ||||||
≤ ULN vs > ULN | 1.100 | 0.235–5.152 | 0.904 | |||
CA15–3 | ||||||
≤ ULN vs > ULN | 3.000 | 0.264–34.052 | 0.353 |